Vernalis is a world leader in structure and fragment-based drug discovery, with an excellent track record for innovation and delivery of clinical candidates in a range of therapeutic areas.
Our research team, based in Granta Park Cambridge combines extensive drug discovery experience with an appetite to innovate, explore and apply the most appropriate techniques, such as fragment-based drug discovery to identify new medicines. It’s this ability to integrate different approaches to solve problems in drug discovery which sets Vernalis research apart. This innovative approach coupled with our technologies and is why companies
around the world seek to collaborate with us.
Over the past five years Vernalis has expanded its external research collaborations, resulting in successful projects with major pharma companies, including Asahi Kasei Pharma, Genentech, GSK, Lundbeck, Novartis and Servier.
Granta Park, Cambridge CB21 6GB
Tel: +44 (0)1223 895555 Fax: +44 (0)1223 895556